Treatment Options in Metastatic Castration-Resistant Prostate Cancer: A Year In Review
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Urocross shows sustained benefit through 24 months post-removal
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
5